| Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity CW Li, SO Lim, W Xia, HH Lee, LC Chan, CW Kuo, KH Khoo, SS Chang, ... Nature communications 7 (1), 12632, 2016 | 1024 | 2016 |
| Mechanisms controlling PD-L1 expression in cancer JH Cha, LC Chan, CW Li, JL Hsu, MC Hung Molecular cell 76 (3), 359-370, 2019 | 875 | 2019 |
| Deubiquitination and stabilization of PD-L1 by CSN5 SO Lim, CW Li, W Xia, JH Cha, LC Chan, Y Wu, SS Chang, WC Lin, ... Cancer cell 30 (6), 925-939, 2016 | 714 | 2016 |
| Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1 JH Cha, WH Yang, W Xia, Y Wei, LC Chan, SO Lim, CW Li, T Kim, ... Molecular cell 71 (4), 606-620. e7, 2018 | 675 | 2018 |
| Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1 CW Li, SO Lim, EM Chung, YS Kim, AH Park, J Yao, JH Cha, W Xia, ... Cancer cell 33 (2), 187-201. e10, 2018 | 539 | 2018 |
| Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth Y Yang, CW Li, LC Chan, Y Wei, JM Hsu, W Xia, JH Cha, J Hou, JL Hsu, ... Cell research 28 (8), 862-864, 2018 | 451 | 2018 |
| STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion JM Hsu, W Xia, YH Hsu, LC Chan, WH Yu, JH Cha, CT Chen, HW Liao, ... Nature communications 9 (1), 1908, 2018 | 393 | 2018 |
| Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression Q Hu, Y Ye, LC Chan, Y Li, K Liang, A Lin, SD Egranov, Y Zhang, W Xia, ... Nature immunology 20 (7), 835-851, 2019 | 305 | 2019 |
| IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion LC Chan, CW Li, W Xia, JM Hsu, HH Lee, JH Cha, HL Wang, WH Yang, ... The Journal of clinical investigation 129 (8), 3324-3338, 2019 | 301 | 2019 |
| TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis Z Jiang, SO Lim, M Yan, JL Hsu, J Yao, Y Wei, SS Chang, H Yamaguchi, ... The Journal of clinical investigation 131 (8), 2021 | 247 | 2021 |
| Palmitoylation stabilizes PD-L1 to promote breast tumor growth YI Yang, JM Hsu, L Sun, LC Chan, CW Li, JL Hsu, Y Wei, W Xia, J Hou, ... Cell research 29 (1), 83-86, 2019 | 224 | 2019 |
| Targeting glycosylated PD-1 induces potent antitumor immunity L Sun, CW Li, EM Chung, R Yang, YS Kim, AH Park, YJ Lai, Y Yang, ... Cancer research 80 (11), 2298-2310, 2020 | 135 | 2020 |
| Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing LL Sun, RY Yang, CW Li, MK Chen, B Shao, JM Hsu, LC Chan, Y Yang, ... American journal of cancer research 8 (7), 1307, 2018 | 124 | 2018 |
| ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer RCE Hsieh, S Krishnan, RC Wu, AR Boda, A Liu, M Winkler, WH Hsu, ... Science immunology 7 (72), eabl9330, 2022 | 100 | 2022 |
| CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer L Nie, Y Wei, F Zhang, YH Hsu, LC Chan, W Xia, B Ke, C Zhu, R Deng, ... Nature communications 10 (1), 5114, 2019 | 89 | 2019 |
| Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer YH Hsu, J Yao, LC Chan, TJ Wu, JL Hsu, YF Fang, Y Wei, Y Wu, ... Cancer research 74 (17), 4822-4835, 2014 | 77 | 2014 |
| New approaches on cancer immunotherapy JH Cha, LC Chan, MS Song, MC Hung Cold Spring Harbor perspectives in medicine 10 (8), a036863, 2020 | 76 | 2020 |
| Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer B Shao, CW Li, SO Lim, L Sun, YJ Lai, J Hou, C Liu, CW Chang, Y Qiu, ... American journal of cancer research 8 (9), 1837, 2018 | 75 | 2018 |
| Thymosin beta 4 induces colon cancer cell migration and clinical metastasis via enhancing ILK/IQGAP1/Rac1 signal transduction pathway MC Tang, LC Chan, YC Yeh, CY Chen, TY Chou, WS Wang, Y Su Cancer letters 308 (2), 162-171, 2011 | 63 | 2011 |
| Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers CC Yang, A LaBaff, Y Wei, L Nie, W Xia, L Huo, H Yamaguchi, YH Hsu, ... American journal of translational research 7 (6), 1009, 2015 | 47 | 2015 |